Preformulation intermediate is used for the Direct compressible and that comprises active substance and excipients. Preformulation intermediate is a combination of substance that is used as a raw material for producing pharmaceutical products and quality of preformulation intermediate has significant effect on safety and efficacy of medication.
Preformulation intermediates are the components of both quality and cost of the pharmaceutical products. Manufacturing of pharmaceutical products occurs in two steps, firstly raw material convert into preformulation intermediate or active pharmaceutical ingredients and then final product create by mixing of preformulation intermediate and other non-active ingredients such as excipient and pressing into tablets. Market of preformulation intermediates is too competitive with other producers. Preformulation intermediates is used in Dermal, Ophthalmic, Nasal and OTC drug formulations. Market of preformulation intermediate comprises different product segment such direct compression granules and capsule filling and micro encapsulated preformulation intermediates.
Preformulation intermediate is used in the selection of drug candidate, selection of formulation components, active pharmaceutical ingredients and among others drug manufacturing process. Basically Preformulation intermediate is used in formulation and development of new dosage form. Process of preformulation begin when synthesized drug show pharmacologic indication in animal models to evaluation in man.
The growing production of Preformulation intermediate for pharmaceutical product development is expected to drive the revenue generation in the global Preformulation intermediate market. The increasing demand for Preformulation intermediate in new applications for emerging fields such as development of new dosage form and Continuous research in biopharmaceuticals is rising the development of novel products has been increased.
Preformulation intermediate manufacturing method is used for developments of pharmaceutical product especially for tablets because 90 % of therapeutic compound are administered by oral route so for which tablet dosage form is more preferable and . However stringent regulatory requirement, government regulations and unfavourable drug price control policies across various countries and market forces are expected to restrain the growth of the global Preformulation intermediate market
The global market for Preformulation intermediate is expected to generate significant revenue with a moderate growth over the forecast period. Rising in demand for biopharmaceuticals and technological advancements such as hydrogenation, Amination, electrochemisty, acetylene other technologies are used to manufacture these intermediates and other applications thus there exists a high competition among local and regional players in the Preformulation intermediate market.
Among product types, the Preformulation intermediate including generic drug, over the counter drugs and innovative drugs is expected to lead the global Preformulationintermediate market over the forecast period. Increasing number of FDA approved new molecular entities and higher price commanded by innovative APIs is expected to increasing market of preformulation intermediate. Research centers and institutes in the end user segment is also expected to contribute high revenue share in the globalPreformulation intermediate market as a majority of demand generated from end user segment.
Geographically, the global Preformulation market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). Among these, North America is expected to be the dominant regional market for Preformulation intermediate owing to high presence of major pharmaceutical companies and better infrastructure.
Also, the set-up of numerous research laboratories in the region is further expected to drive revenue generation in the region over forecast period and in this region is attributed to increasing prevalence of diabetes and cardiac disease.The Preformulation intermediate market inAsia Pacific excluding Japan is expected to grow due to presence of large number of contract manufacturing organization. Europe is expected to register second large share in the global Preformulation intermediate market.
The global Preformulation intermediate market registers presence of large number of domestic manufacturers. Examples of some of the key players operating in the global Preformulation intermediate market are Pfizer Inc., Novartis International AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan, Inc., Boehringer Ingelheim, Sanofi, AbbVie, Eli Lilly and Company, AstraZeneca Plc., Bristol-Myers Squibb, and GlaxoSmithKline plc. among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Global Preformulation intermediate market can be segmented on the basis of Drug Type, Active pharmaceutical ingredients, Type of drug, application, Synthesis and end user.
Based on Drug Type and methods, the global Preformulation intermediate market is segmented as:
Based on Active pharmaceutical ingredients, the global Preformulation intermediate market is segmented as:
Based on Application, the global Preformulation intermediate market is segmented as:
Based on Synthesis, the global Preformulation intermediate market is segmented as:
Based on end user, the global Preformulation intermediate market is segmented as:
Explore Similar Insights
Preformulation intermediates Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
